
Capricor Shares Drop After FDA Rejects DMD Cell Therapy Application
Capricor Shares Tumble After FDA Rejects Cell Therapy for Duchenne Cardiomyopathy Over Efficacy Concerns Capricor Therapeutics suffered a major regulatory setback Friday after the U.S. Food and Drug Administration (FDA)…












